Aim: CD30+ diffuse large B-cell lymphoma (DLBCL) has emerged as a new immunophenotypic variant of DLBCLs. However, the prevalence of CD30 positivity is variable according to different studies, and the prognostic significance of CD30 is also controversial. This study aimed to investigate the positive expression rate and prognostic impact of CD30 in DLBCLs and try to find the correlated influences.
Methods: A total of 241 patients with DLBCL in east China from 2008 to 2015 were included to investigate the prevalence, clinicopathological features and outcomes of CD30+ DLBCLs. Immunohistochemical evaluation for CD10, CD30, BCL2, BCL6, MUM1/IRF4, MYC and Ki67, and fluorescence in situ hybridisation for MYC and BCL2 gene alterations were performed.
Results: Using a >0% threshold, CD30 expression was detected in approximately 10% patient with DLBCL. These predominately presented with centroblastic or anaplastic morphological patterns, less frequently showing immunoblastic morphology or 'starry sky' pattern, mutually exclusive with MYC gene rearrangement, and negatively associated with BCL2 protein expression. CD30 expression was associated with a favourable prognosis of patients' outcomes. However, the multivariate analysis revealed that it was not an independent prognostic factor in DLBCLs. The impact of CD30 might be influenced by the international prognostic index and the expression of MYC and BCL2 proteins.
Conclusion: CD30+ DLBCL may be a subset of DLBCLs with characteristic clinicopathological features, but the prognostic role of CD30 is limited.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/jclinpath-2018-205039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis.
Leukemia
January 2025
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC) is a minor diagnostic criterion for systemic mastocytosis (SM) in the classification of the World Health Organization and International Consensus Classification. So far, it remains unknown whether expression of these antigens on MC is of prognostic significance in SM. We performed a retrospective multi-center study of patients with SM using the data set of the registry of the European Competence Network on Mastocytosis, including 5034 patients with various MC disorders.
View Article and Find Full Text PDFDiagnostic challenge presented by extranodal NK/T cell lymphoma expressing CD20, CD30 and CD15: A case report.
Oncol Lett
March 2025
Gansu Province Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China.
The atypical expression of immune phenotypes in lymphoma is often associated with a poor prognosis and presents diagnostic challenges. The present study reports on a rare extranodal NK/T cell lymphoma. In addition to typical morphology and immunohistochemical characteristics, these tumors strongly express CD20 and CD30 and partially express CD15, which is associated with aggressive clinical behavior.
View Article and Find Full Text PDFRecent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression.
Onco Targets Ther
January 2025
Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Brentuximab vedotin (BV) is an antibody-drug conjugate that combines the CD30 monoclonal antibody with the microtubule-disrupting agent, monomethyl auristatin E, which induces apoptosis in the tumor cell upon its release from the conjugate. The safety and efficacy of BV have been assessed in several studies in patients with T- and B-cell lymphomas. This article reviews the currently available data on the distribution of CD30 expression in T- and B-cell lymphomas, as well as the various levels of CD30 positivity cutoff used in the literature.
View Article and Find Full Text PDFPhase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
Clin Cancer Res
December 2024
Baylor University Medical Center, Dallast, Texas, United States.
Purpose: Brentuximab vedotin (BV) is hypothesized to selectively deplete T regulatory cells (Tregs) that express CD30 and re-sensitize tumors to anti-(PD-1) therapy. This study evaluated responses to BV+pembrolizumab post PD-1 and explored corresponding biomarkers.
Methods: 55 patients with metastatic non-small cell lung cancer (NSCLC) and 58 with metastatic cutaneous melanoma received ≥1 dose of BV+pembrolizumab.
Peripheral T-Cell Lymphoma Following Treatment of Hodgkin Lymphoma: Report of One Case and Literature Review.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
December 2024
Department of Hematology, The First Hospital of Lanzhou University,Lanzhou 730000,China.
This article reports a patient with peripheral T cell lymphoma following treatment of Hodgkin lymphoma.The biopsy of cervical lymph node initially confirmed classic Hodgkin lymphoma,with Reed-Sternberg cells expressing CD30 and B cell-specific activator.After 2 years,the disease progressed and the patient was diagnosed with peripheral T-cell lymphoma (non-specific type) by lymph node biopsy,with the expression of CD3,CD4,and CD8.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!